{"transactions":[{"id":4616100,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-11T21:10:20.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in twelve (12) equal monthly installments following the grant date."}],"balance_after":185000,"derivative":{"exercise_price":1.78,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001104659-26-107120","document":"tm2625227-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465926107120/tm2625227-1_4seq1.xml","form_type":"4"}},{"id":1475590,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T16:15:52.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":650000,"derivative":{"exercise_price":1.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001104659-24-072820","document":"tm2417512-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465924072820/tm2417512-2_4seq1.xml","form_type":"4"}},{"id":1770578,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-02T16:39:08.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":49350,"price":0.51,"value":25168.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023."}],"balance_after":56318,"source":{"system":"sec-edgar","filing":"0001104659-23-105925","document":"tm2327413d2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465923105925/tm2327413d2_4seq1.xml","form_type":"4"}},{"id":1884849,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-19T20:07:32.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time."}],"balance_after":300000,"derivative":{"exercise_price":0.2834,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-23-062814","document":"tm2316383-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465923062814/tm2316383-3_4seq1.xml","form_type":"4"}},{"id":2086650,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-14T20:13:35.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.51,"expiration_date":"2032-12-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-127085","document":"tm2232745-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465922127085/tm2232745-1_4seq1.xml","form_type":"4"}},{"id":2228162,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-17T16:01:33.000Z","date":"2022-06-16","kind":"purchase","acquired":true,"shares":12000,"price":1.27,"value":15240.0,"ownership":{"direct":true},"balance_after":139377,"source":{"system":"sec-edgar","filing":"0001104659-22-072369","document":"tm2218778-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465922072369/tm2218778-1_4seq1.xml","form_type":"4"}},{"id":2361296,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T18:12:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining Stock Options shall vest and become exercisable in twenty-four (24) equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":52000,"derivative":{"exercise_price":2.12,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001104659-22-029439","document":"tm225233-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465922029439/tm225233-3_4seq1.xml","form_type":"4"}},{"id":2414341,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":89784,"kind":"person","name":"Fitzgerald Thomas A","position":1,"cik":"0001854168","reported_name":"Fitzgerald Thomas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T06:04:19.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":33000,"derivative":{"exercise_price":2.45,"expiration_date":"2031-01-31","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-22-011083","document":"tm225233-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854168/000110465922011083/tm225233-2_4seq1.xml","form_type":"4"}}]}